feedback capit market day
attend sanofi capit market day boston present takeaway
event well detail note break-out session compani strategi
financi vaccin specialti care
upbeat present manag team high confid new margin
target margin trajectori expect
back-end load oper invest deliv save eg absorb
high confid dupix peak sale target driven continu growth
ad asthma expans new indic new geographi new age group
paediatr ad sanofi believ robust defens dupix emerg
competit jak base safeti efficaci profil dupix npv /share
total sanofi npv
vaccin revenu growth target mid high singl digit driven roll
high dose quadrival flu pentaxim china booster vaccin underpin
expand manufactur capac expect posit revenu mix drive addit
margin upsid vaccin
robust present six focu mid/lat stage pipelin asset john reed
head biggest surpris focu differenti potenti
catalyst risk earli deliveri margin growth target proof
concept btk multipl sclerosi fda decis pathway over-the-counter ciali
valuat sanofi trade price-to-earnings discount eu major ex azn
pharmavalu ev/npv sanofi trade compar eu peer
valuat metric
price-to-earnings rel local market
number share
price rel chart measur perform
close
spot exchang rate
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
sanofi-aventi pharmaceut group engag research
develop manufactur market healthcar product
sanofi pasteur
blue sky scenario assum full pipelin success stronger
growth rate diabet
grey sky assum pipelin success greater declin
diabet driven greater gener competit lantu poor uptak
lixilan
price rel chart measur perform close
spot exchang rate
summaris key point made ceo paul hudson introduct hudson
aim set target achiev beat
initi thought opportun sinc take
untap potenti core asset
predict long term franchis portfolio vaccin consum
promis scienc prioritis invest
world class engag talent peopl compani better
raw materi hudson found way better expect
year plan two phase
refocu decis action
growth win asset
agil effici resourc deploy
 day like june
abl go much deeper pipelin
focu growth need strengthen portfolio prioritis
lead innov longer pursu especi late
acceler effici decis action expand margin
re-empow talent reinvent sanofi work give peopl respons back
dupix peak sale efficaci safeti key differenti
vaccin mid high singl digit growth want spin engin faster
pipelin priorit acceler portfolio
market type inflamm competit
put jak place abl compet vs dupix
atop dermat chang live understand younger end popul scale number
patient treatment unlik anyth biolog
treat pt adult elig popul
asthma year time align cumul dupix highest share elig
dupix biolog patient biolog naiv confid treat
uticaria larg opportun pt copd hard treat
ambit
take psoriasi market would asset
mid-to-high singl digit sale growth sale
clearli pediatr vaccin compani choic flu
uniqu differenti high dose flu
lost live due complic influenza franc
need high dose pull
rsv revenu
hemophilia hemlibra patient dynam conveni
serd master switch endocrin signal hr breast cancer
venglustat real chanc rare diseas
rsv nirsevimab cost-effect rsv prophylaxi infant
btk mani say btk sanofi know btk cross
ask patient doc chang market mani patient
will switch hemlibra
asleep wheel deal bioverativ hemlibra
less hemlibra monthli
patient switch conveni dose
underestim mobil patient
hemlibra patient acut bleed
involv faslodex
readout end
move earlier stage safeti profil
role lsd kidney
open question role parkinson
understood complex pick high risk patient
need make someth avail infant
vaccin price mab
btk ms
awar uptak b-cell deplet iv use soon subcutan use
btk b-cell deplet deactiv reactiv
competitor btk cross blood-brain-barri
respect work aubagio think disrupt
poc readi go phase studi
world expert sanofi
ga t-cell mostli like theori time
believ pick best class becom major player come next
pipelin well place combin
target boi margin
need understand manag busi doubl profit
think bold still behind peer group
diabet cv
portfolio signific declin
outstand perform market pressur us complex around
discontinu diabet cv research dont think asset pipelin
right size commerci model intern praluent model chang regeneron
understand scope boundari around regeneron relationship
kevzara praluent harder make progress
praluent step back us keep praluent rest world
wont launch continu develop cost entri high
onduo jv verili digit relationship signific invest harder nut crack longer
progress invest still investor oper expens
vertic horizont gbu structur report line slow
ask simplifi
consum health
consum agil enough move speed current
separ unlock valu fulli integr separ complet stand-alone
need acceler digit grow fast market
time-frame two rx-to-otc switch growth opportun ciali tamiflu
expect take growth point
dont know volum turn never done
goal beat expect volum china
launch mostli specialti driven flu
empower account
matrix
miss opportun global local align disciplin build global
cultur account top leader incentiv tsr total sharehold
sanofi commit csr focu
start art factori almost self-suffici term water electr emiss
compani better hudson thought
compani procrastin past decis make
hudson fulli support board
busi oper incom margin reach ambit
deprioritis busi
smart spend reduc demand right size spec negoti price
oper experi manufactur effici organis product
chang mindset
cut travel expens
cut consult fee- cut train budget
cut headcount support function
cut real estat much come
save expect demand manag specif design price
spend
save
oper excel manufactur
digit acceler aim reduc lead time month deliv
decreas plant cycl time
digitalis ai forecast reduc inventori level day
optim cmo supplier reduc baselin
tail product sell net sale per annum
aim reduc product
base
take improv work capit
organ invest pipelin
anti-dilut share buyback like ep growth driven oper perform
exit invest primari care area
want build new platform drug discoveri ab design ablynx acquisit provid
access nanobodi platform
lot emphasi pace deliveri
four ps focu pipelin peopl patient pace
use committe decid pipelin cut
shift inorgan organ product come pipelin
product intern acquir earli lot econom
 pathway origin evolv parasit protect
necessari develop world therefor safe drug pathway
main gatekeep inflammatori pathway inhibit
better inhibit one
signal turn jak famili kinas want block jak signal
block actual jak protein would need block would give
lot collater damag
expand adjac type indic prurigo nodulari chronic spontan
medic record use mine candid indic
challeng patient stay rigor schedul
home iv admin burden patient
fitusiran conveni monthli dose sirna data show bleed per year
better emicizumab fold broader profil monthli inject antidot
safeti equal fitusiran hemlibra
treatment allow day near-norm fviii activ allow lifestyl
similar non-hemophilia patient long half-lif almost two day
prevent bleed joint one import endpoint
serd degrad receptor complet stop activ
fulvestr approv given larg volum intramuscular inject cant give
enough drug either
start pivot studi mono submiss target
daili medic still debat dose indic
much longer durat synergi
singl inject birth born-in-season infant
unmet need babi lead caus hospitalis
fda breakthrough design ema prioriti medicin
infant immun system isnt compet make immun respons
month passiv immunis nirsevimab last cover first month
target submiss
block first step glycosphingolipid pathway
lysosom storag diseas lipid accumul get variou diseas
lsd gaucher diagnos pt us europ japan
adpkd suffer us eu japan ww
parkinson lipid bind alpha-synuclein common predisposit gba gene mutat
one mutat parkinson two mutat gaucher need includ patient
without gba mutat incas affect larg popul
still remain lot unmet need
btk express b-cell btk requir b-cell function
drug shut b-cell doesnt kill b-cell
btk also express microgli cell brain therefor target cell
ocrevu evobrutinib dont get brain
target effect seen
poc r/r ms earli next year launch studi stage ms good
like platform pipelin
manag expand genet code
add amino acid let modifi amino acid tune receptor
lymphokin bind
engin form
signific synergi sanofi novel platform
exit comb t-cell engag
make massiv increas nk cell cell
possibl combin compani molecul
first-in-class treatment cad new soc refractori itp
stimul complement system lyse red blood cell
first ert asmd top-line data jan
 think path margin target linear
gener linear aubagio loe bump road give clariti pathway
margin year year progress move forward
 previous cfo didnt want cost save target one chang
new ceo given much clariti prioriti invest work
product need target aim clear deliver
 potenti divest stake
reason exit sake exit would dilut someth
compel come along money deploy valu
 prioriti list
need leav someth day cecam need see commerci
opportun build cecam posit cancer understand big could
shortli enter studi amgen kra
 pharma top-line target
challeng total revenu guidanc pick key product divis
premium high current even earlier scienc want transform scienc
want leverag exist portfolio synthorx good exampl bolt
firepow peopl expect build cash flow build
 cost save program realli new
ye deeper speed emphasi greater previous lack extrem
prioritis want realli focu specif area cost save rather take bit
 free cash flow guidanc lower peopl expect
restructur charg cost cost save program
 emerg market seem underrepres remark
think best industri em capabl growth continu establish product portfolio
still strong growth diabet franchis
 pipelin asset develop intern risk
guid goal need improv intern product best access win
whether intern extern platform acquisit mean better toolbox sanofi
 ablynx synthorx
 fitusiran key candid
hudson expect like fitusiran join understood patient
dynam haemophilia becam interest
 strong belief board barrier invest scienc
exactli opposit hudson experienc strong focu scienc around
synthorx deal strateg review board product balanc debat
 littl focu new modal
gene therapi area focu repurpos vaccin facil make aav viral vector
 flow gener oper balanc sheet
need focu heavili inventori off-set build biolog inventori usual
need higher stock larg growth oper
 china dupix launch role digit drive growth
china approv end unmet need respiratori china dupix
growth driven ad indic ad age group ad geographi
mrna deal translat littl behind focus also littl behind
adjuv address recent deal also work new area vaccin
manag financ strategi
 much cost save reinvest
everyth reinvest posit abl reinvest
sign growth driver come clear level
need save access amount
confid peak sale target type inflamm market
type inflamm market underdevelop safeti profil
difficult dislodg us price come market grow long
larg share volum growth offset
 strateg review takeaway find improv upon
staff excel wrongli assum low moral wrongli assum averag qualiti
staff total opposit poor align resourc dispassion view pipelin
key good asset peopl worri failur werent
go push envelop reaction fact manag back mean
speed organis acceler quickli btk good exampl readi
phase posit poc alreadi screen patient studi advanc
gene therapi chang address
 decis shut diabet cvd research go impact commerci
isnt anyth transform pipelin make sens continu
think cvd asset opportunist still lot opportun eg china divest
agenda someon interest fine easi imagin happen
didnt want wast money
 new structur consum mean busi
done lot work post-bi stand-alone still integr regulatori led
slow abil execut opportunist move consum need
applic vs larg pharma co
lot gene therapi compani talk sanofi san know patient could definit
come challeng vector etc offset realli excit
innov oral
 gene therapi hous aav lenti need
reach moment decid organ need soon share wont
enough dabbl open mind
growth us market histor come switch real
regulatori challeng ciali difficult class discuss regul
open clear recognis class switchabl sanofi undertaken develop
path line fda confid meet fda present new data
increas sanofi confid switch abil actual use studi need
higher probabl signal go actual use studi launch time
 need spend order deliv growth
absolut trap enough resourc fund invest
need sanofi spend money pharma co margin deliveri
definit back end load front load either need momentum build
 backdrop us polit price assumpt behind plan
fundament assumpt innov reward us see
progress senat financ committe bill strongli believ patient benefit
innov reward
 praluent innov didnt get reimburs
key remov volum barrier compet price
 consum sanofi best owner pharma focu benefit compani
sourc fund right
good busi gener cash chang us polit landscap uncertain
mayb hold stabl cash gener asset good idea soon make decis
simpli consid sale need think hasnt chanc
show deliv catalyst around over-the-counter switch
sanofi time bolt-on bring good scienc dupix uniqu asset
lot visibl growth synthorx option cfo extrem
support bring growth driver drive acceler mid-term time horizon
gene therapi must capabl leader rare diseas made lot invest
vector engin capsid engin bring cgmp manufactur line genom
edit collabor sangamo look cell base therapi multi specif antibodi
critic new class
 midterm potenti agglutinin diseas
data cad good well receiv larger potenti role complement
pathway could broader util autoimmun diseas indic itp proof
concept data goal would take disord diseas understand
mean sanofi could target rare autoimmun haemolyt diseas look basket trial
interest target revolut medicin asset singl agent poc on-going work
combo studi egfr mek
dose find trial modern design use dose respons curv rather point
dose select dose report daili compar
teriflunomid rrm ppm spm vs placebo
 oncolog pipelin
sanofi right combin libtayo anyth sanofi pipelin veto
risk harm pt use libtayo combo partner synthorx libtayo
strategi base combin partner isatuximab may differenti need see
data see strong commit multipl myeloma mid stage asset serd
earli stage interest bispecif nk cell engag
 illustr lower dose slide dose
dose keep cmax normal rang give good weekli coverag
 contrast rsv strategi gsk matern vaccin strategi
matern vaccin complex pre-term infant full coverag
need protect
 serd esmo data still gi tox
look data recent present import look patient
variabl pretreat resist
tame molecul pleiotrop effect synthorx technolog
allow pegyl extend half-lif peg stay unlik nektar molecul pegyl
elimin interact remov much downstream problem
suppress cell eosinophil expans roch use antibodi tether localis
immunogen roch report anti-drug antibodi
vacelix paediatr vaccin
build capac launch
pleas gsk seem de-emphasis us
need grow capac order cover boost
new capac ad canada allow move market
launch us
geograph expans strain high dose alreadi reimburs canada
success launch
strong growth
fluzon high dose babi
babi get standard dose immun system underdevelop high dose could
april us oct europ
broader age rang label open new market
 margin leverag get upgrad flu high dose quadrival
significantli greater cog price increas offset high dose
flu growth help drive margin
 high dose flu competit hurdl high
egg base flu vaccin lot complex antigen
dose illustr complex sanofi fail high dose three valent took lot
effort get high dose four valent also data set patient studi show superior
normal dose extrem difficult replic
 flublock sale
sold dose ad million dose everi year kaiser trial on-going look
flublock follow electron medic record give lot data subgroup
like asthmat copd etc pt year year read
 much capac headroom
build pentacel toronto facil readi build two new facil vaxigrip
alreadi huge capac flublock
 gsk efficaci high
enter enthusiast wont comment detail highli competit
higher pharma today also grow add total sanofi margin
 new ceo want drive product vaccin
limit new mode near term excit high dose flu came
lot trial support growth driver
 china growth driver
pentaxim remain signific driver growth
sanofi lot access adjuv lag get adjuv clinic
alreadi brought clinic follow
 gsk adjuv took get market quicker
piggi back gsk valid mechan tri speed time market
 geograph go market model shingrix go self-pay high price
strategi depend much capac ad capac want roll
dupix critic driver epidemiolog type inflamm underpin potenti
hematolog two asset pipelin haemophilia could best class
isatuximab late market still second may differenti
diseas key franchis sanofi
 aspir dupix target ip peak
recal exclud copd indic would addit better view
peak get forecast base ad asthma pillar ip
 hudson leadership chang commerci organis
increas commit phase rapid sale forc deploy
expans faster decis broader develop program first day hudson
select new dupix indic made public agre detail
broad medic affair strategi previous drive growth
 includ dupix target
indic except copd risk adjust china sale includ
 detail chang relationship kevzara praluent
product lower prioriti still opportun need smart
physician enthusiasm big market sanofi got
innov combo mm clinic advantag time vs daratumumab
posit daratumumab non-respond wait see data subcutan label
sanofi believ drug less clean peopl expect requir post
dose monitor number dose first dose infus chair time still
signific thu big differenti
 use price late market asset late entrant ad use price
dupix
price sustain lever need innov
 aubagio growth outlook face ofatumumab ocrevu
still expect growth slow given competit gear invest
aggress btk trial order tri make first market ms best class
 diseas growth import gene therapi platform
deliv far better growth predict genzym acquisit see limit threat
exist franchis gaucher diseas lot unmet need one gene therapi
clinic fabri diseas also limit unmet need pomp diseas year myozym
data show stabl diseas patient need sanofi other
gene therapi program challeng go liver target muscl sanofi see gene
therapi open new rare diseas growth opportun import platform
 bonu non-respond dupix switch new modal arriv
atop dermat
patient persist dupi first symptom back stop therapi itch
drive persist drug wouldnt want non respond stay drug
dupix work itch day interest jak tri carv itch
nich black box warn see much bigger focu slightli
faster resolut itch
 delay fitusiran studi recruit
sanofi get distract safeti event slow recruit
addit patient recent atrial clot complic patient request
resum fitusiran see enthusiasm build amongst doc
 plan gene therapi hemophilia
earli collabor san rafael
product sale eur prob prob vaccin med sanofi genzym ms/onc/rar diabet cardiovascular ex vaccin sale oper margin margin margin profit op incom op incom profit cs rate sanofi core associ incom incom charg relat share data share outstand fd cs ep ep lc consolid charl martineau univers toronto decemb
compani mention price
